FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016108812> ?p ?o ?g. }

• W3016108812 endingPage "12" @default.
• W3016108812 startingPage "1" @default.
• W3016108812 abstract "Most of the clinically available monoclonal antibody (mAbs) drugs are Immunoglobulin G's (IgG's). The variability of the IgG subclasses is in the amino acid content of the hinge region which forms the basis of their stability and suitability for therapeutics development. Monoclonal antibody drug development is a tedious and long-term process requiring putting many factors into consideration. The variability in the stability, flexibility, mediation of antibody dependent cell cytotoxicity (ADCC), mediation of cellular dependent cytotoxicity (CDC), and C1q protein binding are major factors that determine the suitability of IgG subclasses for the development of therapeutics. It was reviewed that most of the marketed mAbs therapeutics are IgG1 subclass, this is due to its stability and less aggregate formation, triggering of effector function via the action of Fc domain binding to FcyRI, FcyRII, and FcyRIII, resulting to mediation of ADCC, CDC, and C1q cascade of signaling. However, IgG2 is also utilized for the development of therapeutic when neutralization of soluble antigen with reduce effector function is required, with some drugs in late stage development and also approved for commercial use. Also, IgG4 is utilized for the development of therapeutics drugs when the recruitment of the host effector function is not required. But IgG3 utilization for the development of therapeutics requires engineering of the amino acids content of the hinge region, without any commercially available drug that is IgG3. This review examines the suitable IgG subclasses with the capability of ADCC, CDC, and C1q mediation, and also provides future recommendation on the suitability of less stable IgG subclasses in the therapeutic development." @default.
• W3016108812 created "2020-04-17" @default.
• W3016108812 creator A5063363561 @default.
• W3016108812 date "2020-01-01" @default.
• W3016108812 modified "2023-09-23" @default.
• W3016108812 title "The Best IgG Subclass for the Development of Therapeutic Monoclonal Antibody Drugs and their Commercial Production: A Review" @default.
• W3016108812 cites W1488966816 @default.
• W3016108812 cites W1545888829 @default.
• W3016108812 cites W1578638511 @default.
• W3016108812 cites W1590801360 @default.
• W3016108812 cites W1594992446 @default.
• W3016108812 cites W1976394313 @default.
• W3016108812 cites W1977353548 @default.
• W3016108812 cites W1980594873 @default.
• W3016108812 cites W1985102822 @default.
• W3016108812 cites W1986864699 @default.
• W3016108812 cites W2003326194 @default.
• W3016108812 cites W2004290717 @default.
• W3016108812 cites W2005911076 @default.
• W3016108812 cites W2010948143 @default.
• W3016108812 cites W2023024432 @default.
• W3016108812 cites W2038319340 @default.
• W3016108812 cites W2040135401 @default.
• W3016108812 cites W2042712910 @default.
• W3016108812 cites W2044410500 @default.
• W3016108812 cites W2045059243 @default.
• W3016108812 cites W2050405684 @default.
• W3016108812 cites W2050754173 @default.
• W3016108812 cites W2066833805 @default.
• W3016108812 cites W2084271278 @default.
• W3016108812 cites W2088135299 @default.
• W3016108812 cites W2089542574 @default.
• W3016108812 cites W2094955456 @default.
• W3016108812 cites W2110990893 @default.
• W3016108812 cites W2134238361 @default.
• W3016108812 cites W2135643937 @default.
• W3016108812 cites W2250059298 @default.
• W3016108812 cites W2338733954 @default.
• W3016108812 cites W2410420426 @default.
• W3016108812 cites W2606083379 @default.
• W3016108812 cites W2613868166 @default.
• W3016108812 doi "https://doi.org/10.35248/1745-7580.20.16.173" @default.
• W3016108812 hasPublicationYear "2020" @default.
• W3016108812 type Work @default.
• W3016108812 sameAs 3016108812 @default.
• W3016108812 citedByCount "1" @default.
• W3016108812 countsByYear W30161088122021 @default.
• W3016108812 crossrefType "journal-article" @default.
• W3016108812 hasAuthorship W3016108812A5063363561 @default.
• W3016108812 hasConcept C109316439 @default.
• W3016108812 hasConcept C14036430 @default.
• W3016108812 hasConcept C147483822 @default.
• W3016108812 hasConcept C159654299 @default.
• W3016108812 hasConcept C185592680 @default.
• W3016108812 hasConcept C202751555 @default.
• W3016108812 hasConcept C203014093 @default.
• W3016108812 hasConcept C2776194381 @default.
• W3016108812 hasConcept C2780035454 @default.
• W3016108812 hasConcept C40677261 @default.
• W3016108812 hasConcept C51785407 @default.
• W3016108812 hasConcept C542903549 @default.
• W3016108812 hasConcept C55493867 @default.
• W3016108812 hasConcept C64903051 @default.
• W3016108812 hasConcept C70721500 @default.
• W3016108812 hasConcept C86803240 @default.
• W3016108812 hasConcept C95444343 @default.
• W3016108812 hasConcept C98274493 @default.
• W3016108812 hasConceptScore W3016108812C109316439 @default.
• W3016108812 hasConceptScore W3016108812C14036430 @default.
• W3016108812 hasConceptScore W3016108812C147483822 @default.
• W3016108812 hasConceptScore W3016108812C159654299 @default.
• W3016108812 hasConceptScore W3016108812C185592680 @default.
• W3016108812 hasConceptScore W3016108812C202751555 @default.
• W3016108812 hasConceptScore W3016108812C203014093 @default.
• W3016108812 hasConceptScore W3016108812C2776194381 @default.
• W3016108812 hasConceptScore W3016108812C2780035454 @default.
• W3016108812 hasConceptScore W3016108812C40677261 @default.
• W3016108812 hasConceptScore W3016108812C51785407 @default.
• W3016108812 hasConceptScore W3016108812C542903549 @default.
• W3016108812 hasConceptScore W3016108812C55493867 @default.
• W3016108812 hasConceptScore W3016108812C64903051 @default.
• W3016108812 hasConceptScore W3016108812C70721500 @default.
• W3016108812 hasConceptScore W3016108812C86803240 @default.
• W3016108812 hasConceptScore W3016108812C95444343 @default.
• W3016108812 hasConceptScore W3016108812C98274493 @default.
• W3016108812 hasIssue "1" @default.
• W3016108812 hasLocation W30161088121 @default.
• W3016108812 hasOpenAccess W3016108812 @default.
• W3016108812 hasPrimaryLocation W30161088121 @default.
• W3016108812 hasRelatedWork W1544799888 @default.
• W3016108812 hasRelatedWork W160930365 @default.
• W3016108812 hasRelatedWork W1967722730 @default.
• W3016108812 hasRelatedWork W2035343873 @default.
• W3016108812 hasRelatedWork W2050305953 @default.
• W3016108812 hasRelatedWork W2050376954 @default.
• W3016108812 hasRelatedWork W2075219903 @default.
• W3016108812 hasRelatedWork W2441590030 @default.
• W3016108812 hasRelatedWork W2504433076 @default.

• next